ANT308 TFA
Based on 1 Customer Validation
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM).
For research use only. We do not sell to patients.
- Purity: 99.57%
- Formula: C156H261N47O40S·xC2HF3O2
- Molecular Weight:3467.10 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All PACAP Receptor Isoforms
More
Biological Activity
ANT308 (0.1-10 μM, 72 h) TFA reduces the viability of B16F10 and HT-144 cells dose-dependently[2].
ANT308 (10 μM, 72 h) TFA decreases the proportion of cells in S phase, and induces apoptosis in B16LS9 and Mel 290 cells[2].
ANT308 (10 μM, 8 h) TFA significantly inhibits cell migration in the B16LS9, Mel290, and HT-144 cell lines[2].
ANT308 (72 h) TFA reduces MCAM and N-cadherin expression by inhibiting VIP-VPAC2 signaling[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:B16F10 and HT-144 cells
-
Concentration:0.1, 1, 5 and 10 μM
-
Incubation Time:72 h
-
Result:Decreased the numbers of viable B16F10 and HT-144 cells by around 46% and 27%, respectively, compared to control cultures with 5 μM twice daily.
-
Cell Line:B16LS9 and Mel 290 cells
-
Concentration:10 μM
-
Incubation Time:72 h
-
Result:Decreased cells in the S phase.
-
Cell Line:B16LS9 and Mel 290 cells
-
Concentration:10 μM
-
Incubation Time:72 h
-
Result:Increased percentages of apoptotic cells.
-
Cell Line:B16LS9, B16F10, Mel 290 cells, HT-144 cells
-
Concentration:10 μM
-
Incubation Time:8 h
-
Result:Significantly inhibited cell migration in the B16LS9, Mel290, and HT-144 cell lines.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B16LS9 induced UVM model and B16LS9 or B16LS9 induced subcutaneous melanoma model established in female C57BL6/J mice (8-10 weeks) and NRG (NOD Rag gamma) mice (10-11 months old)[2]
-
Dosage:100 μg/100 μL PBS
-
Administration:Subcutaneous injection (s.c.), twice a day for 10 days
-
Result:Significantly reduced the number of liver metastases. Reduced MCAM, but had no significant effect on N-cadherin expression. had no significant effect on subcutaneous tumor volume.
Chemical Information
-
Appearance Solid
-
Molecular Weight 3467.10 (free base)
-
Formula C156H261N47O40S·xC2HF3O2
-
Color White to off-white
-
Sequence
Lys-Pro-Arg-Arg-Pro-Tyr-Thr-Ser-Asp-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Leu-Ile-Leu-Asn
-
Sequence Shortening
KPRRPYTSDYTRLRKQMAVKKYLNLILN
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : ≥ 100 mg/mL
* "≥" means soluble, but saturation unknown.
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz